- N14, ITTC Building, Plymouth Science Park
- camille.carroll@plymouth.ac.uk
Profiles
Dr Camille Carroll
Associate Professor and Honorary Consultant Neurologist
Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)
Role
Honorary Consultant Neurologist, Plymouth Hospitals NHS Trust
National Specialty Lead for Neurodegenerative Diseases NIHR CRN
Parkinson’s Specialty Lead and Cluster 4 Clinical Research Lead South West Peninsula CRN
Integrated Clinical Academic Training Lead
Qualifications
Dr Carroll is an academic consultant neurologist. She undertook her preclinical medical training at the University of Manchester,where she also completed an intercalated PhD (1994) investigating NMDA receptor antagonists in models of Parkinson's disease (PD). She completed her clinical training at the University of Oxford in 1997 and undertook specialist neurology training in the South West and West Midlands. In 2007 Dr Carroll was awarded a Medical Research Council fellowship which allowed her to develop research interests investigating neuroprotective mechanisms in cell culture models of Parkinson's disease.
Roles on external bodies
Dr Carroll sits on the Grant Assessment Panel 1 for Parkinson's UK, the Research Committee for the Cure Parkinson's Trust and the Linked Clinical Trials Committee. She has previously chaired the Data Monitoring Committee for the GDNF trial in Parkinson's disease. She is regional representative on the Association of British Neurologists Research Committee. She is a member of the Examination Board and Question Writing Group for the Neurology SCE.
Research interests
Dr Carroll's current research focus is on clinical trials of neuroprotective interventions in Parkinson's disease, currently being the chief investigator of a multi-centre clinical trial of simvastatin as a potential neuroprotective therapy in PD (PD-STAT). She also has an interest in the use of technology (wearable sensors and apps) for early disease detection, personalising therapy and monitoring disease progression. She has overseen the development of a PD DNA bank (2700 samples) and a regional PD clinical research register. She was appointed National Specialty Lead for Neurodegenerative Disease in 2017. She has been PD Speciality Lead, South West Peninsula CRN since April 2014, previously being joint PD Research Director for SW DeNDRoN (2010-2014). She was Chair of the Peninsula Parkinson’s Excellence Network (PenPEN) (2015-2017).
Within University Hospitals Plymouth NHS Trust, Dr Carroll leads development of the Parkinson’s disease service, which won a Parkinson's Excellence Network Award in 2017. She also leads a successful trial delivery team, overseeing a mixed portfolio of Parkinson's clinical studies - commercial and non-commercial, interventional and observational.
Research groups
Key publications are highlighted
Journals
Articles
2019
'Discovery of Volatile Biomarkers of Parkinson’s Disease from Sebum'
ACS Central Science
5,
(4)
599-606
, DOI
PEARL
2019
'Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease'
Molecular Brain
, DOI
PEARL
2018
'Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease'
Movement Disorders Clinical Practice
, DOI
PEARL
2018
'Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists'
Neurodegenerative Disease Management
PEARL
2018
'Identification of Optimum Panel of Blood-based Biomarkers for Alzheimer’s Disease Diagnosis Using Machine Learning'
2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
, DOI
PEARL
2018
'Machine-learning based identification of undiagnosed dementia in primary care: a feasibility study'
BJGP Open
bjgpopen18X101589-bjgpopen18X101589
, DOI
PEARL
2018
'Exercise for people with Parkinson’s: a practical approach'
Practical Neurology
18,
(5)
, DOI
PEARL
2018
'First comprehensive tool for screening pain in Parkinson's disease: The King's Parkinson's Disease Pain Questionnaire (KPPQ)'
European Journal of Neurology
25,
(10)
1255-1261
, DOI
PEARL
2017
'Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress'
Journal of Parkinson's Disease
, DOI
PEARL
2016
'Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease'
Neurobiology of Aging
48,
222.e1-222.e7
, DOI
PEARL
2016
'Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease'
2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
, DOI
PEARL
2016
'Delta-9-tetrahydrocannabinol protects against MPP<sup>+</sup> toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis'
Oncotarget
, DOI
PEARL
2015
'King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation'
Movement Disorders
30,
(12)
1623-1631
, DOI
PEARL
2015
'LiveWell - Promoting Healthy Living and Wellbeing for Parkinson Patients Through Social Network and ICT Training: Lessons Learnt and Best Practices'
International Journal of Healthcare Information Systems and Informatics
2013
'Molecular genetic studies of neurodegenerative disease'
J Neurol Neurosurg Psychiatry
84,
(11)
, DOI
PEARL
2013
'Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE'
Journal of Neurology, Neurosurgery & Psychiatry
84,
(11)
e2.58-e2
, DOI
PEARL
2013
'Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease'
Acta Neuropathologica
1-7
, DOI
2012
'Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease'
Neuropathol Appl Neurobiol
38,
(6)
535-547
, DOI
2012
'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas'
Glia
60,
(11)
1721-1733
, DOI
PEARL
2012
'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies'
Clin Med (Lond)
12,
(3)
210-215
, DOI
PEARL
2011
'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies'
CLINICAL MEDICINE
12,
(3)
210-215
, DOI
2011
'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease'
Neurochem Int
59,
(1)
73-80
, DOI
PEARL
2010
'Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon'
J Neurol
257,
(12)
2094-2096
, DOI
2010
'Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease'
MOVEMENT DISORDERS
25,
S621-S621
PEARL
2010
'Changes in Iron-Regulatory Gene Expression Occur in Human Cell Culture Models of PD'
MOVEMENT DISORDERS
25,
S628-S628
PEARL
2009
'Cauda equina syndrome following a lumbar puncture'
J Clin Neurosci
16,
(5)
714-716
, DOI
PEARL
2007
'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure'
Neurology
69,
(6)
555-563
, DOI
2007
'The feminisation of British neurology: implications for workforce planning'
Clin Med (Lond)
7,
(4)
339-342
, DOI
PEARL
2005
'Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS'
Neurology
65,
(6)
934-937
, DOI
2005
'Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks'
JOURNAL OF NEUROSCIENCE METHODS
144,
(1)
47-52
, DOI
PEARL
2005
'Muscle cramps and weakness secondary to graft versus host disease fasciitis'
Eur J Neurol
12,
(4)
320-322
, DOI
PEARL
2005
'Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study'
Neurology
64,
(6)
1100-1100
, DOI
2004
'The 'harlequin' sign in association with multiple sclerosis'
JOURNAL OF NEUROLOGY
251,
(9)
1145-1146
, DOI
2004
'Doon-off variations cause discrepancies in the historical items of the UPDRS?'
Movement Disorders
19,
(5)
605-605
, DOI
PEARL
2004
'The effect of cannabis on tremor in patients with multiple sclerosis'
Neurology
62,
(7)
1105-1109
, DOI
2004
'Stroke in Devon: knowledge was good, but action was poor'
J Neurol Neurosurg Psychiatry
75,
(4)
567-571
, DOI
PEARL
2004
'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study'
Neurology
63,
(7)
1245-1250
, DOI
2004
'Provision of 24 hour acute neurology care by neurologists: manpower requirements in the UK'
J Neurol Neurosurg Psychiatry
75,
(3)
406-409
, DOI
PEARL
2004
'Charles Karsner Mills (1845-1931) and his syndrome'
Some Aspects of History of Neuroscience
35-36
2004
'Raised intracranial pressure presenting with spontaneous periorbital bruising: two case reports'
Journal of Neurology, Neurosurgery and Psychiatry
75,
(8)
PEARL
2003
'Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy-like syndrome'
Movement Disorders
18,
(3)
1998
'Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures'
Brain
121,
(4)
659-675
, DOI
1998
'Glutamate antagonists for Parkinson's disease - Rationale for use and therapeutic implications'
CNS DRUGS
9,
(6)
421-429
, DOI
1998
'The pallidotomy debate'
British Journal of Neurosurgery
2,
(12)
1998
'Visual fields in patients with posterior GPi pallidotomy'
1997
'Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action'
Neurosci Biobehav Rev
21,
(4)
469-475
PEARL
1995
'REVERSAL OF PARKINSONIAN SYMPTOMS BY INTRASTRIATAL AND SYSTEMIC MANIPULATIONS OF EXCITATORY AMINO-ACID AND DOPAMINE TRANSMISSION IN THE BILATERAL 6-OHDA LESIONED MARMOSET'
BEHAVIOURAL PHARMACOLOGY
6,
(5-6)
492-507
1995
'Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for treatment of parkinsonian symptoms'
Psychopharmacology
119,
(1)
55-65
, DOI
1993
'Chemical signalling in the globus pallidus in parkinsonism'
Progress in Brain Research
(99)
125-139
Conference Papers
2016
'PD-TAP: AN OBJECTIVE AND AUTOMATED MEASURE OF PARKINSON'S DISEASE SEVERITY'
BMJ
e1.237-e1
, DOI
2016
'LONG-TERM COGNITIVE OUTCOME IN ADULT SURVIVORS OF AN EARLY CHILDHOOD POSTERIOR FOSSA BRAIN TUMOUR'
154-154
2015
'People with Parkinson's design clinical trials charter to improve communication about, recruitment to and retention in Parkinson's clinical trials'
Springer Nature
, DOI
2015
'Two-arm randomised futility trials: PD-stat - a futility trial of a potential neuroprotective treatment in people with Parkinson's disease'
Springer Nature
, DOI
2013
'Accumulation of alpha synuclein in the bowel in preclinical Parkinson's disease'
11-11
2013
'Cannabinoid receptor expression in Parkinson's disease'
34-35
2012
'108 Investigating the neuroprotective properties of Δ9-THC in a cell culture model of Parkinson's disease'
BMJ
e1.58-e1
, DOI
2010
'PAW19 Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease'
BMJ
e29-e29
, DOI
2010
'POMD11 Cannabinoids are neuroprotective in a human cell culture model of Parkinson's disease'
BMJ
e60-e60
, DOI
2007
'A rare complication of a common procedure: Acute cauda equina syndrome following a lumbar puncture'
218-218
2005
'Childhood onset demyelinating neuropathy and cataracts: A potentially treatable disorder'
1323-1324
2005
'Clinical viral encephalitis in adults: A 10 year retrospective study'
157-158
2003
'Meeting the Association of British Neurologists guidelines: Provision of 24 hour acute neurology care by neurologists'
1453-1453
2003
'Stroke in Devon: The need to translate knowledge into action'
1176-1177
2003
'Charles Karsner Mills (1845-1931) and his syndrome'
406-406
Posters
0
'Can implementation of technology transform the management of Parkinson's? Lessons learnt from the Parkinson's KinetiGraph (TM) (PKG (TM)) service evaluation project'
0
0
PEARL
0
'SONAR identifies registrar research training needs in a clinical training program'
0
0
0
'Successful neurology trainee research network collaborative audit'
0
0